carglumic acid (Rx)

Brand and Other Names:Carbaglu

Dosing & Uses

AdultPediatric

Dosage Forms & Strengths

dispersible tablet

  • 200mg

Hyperammonemia Due to NAGS Deficiency

Initiate treatment as soon as N-acetylglutamate synthase (NAGS) deficiency is suspected, which may be at birth

Acute hyperammonemia

  • Indicated as adjunctive therapy to standard of care for acute hyperammonemia due to NAGS deficiency
  • 100-250 mg/kg/day PO divided into 2-4 doses; round to the nearest 100 mg (ie, half of a tablet)
  • During acute episodes, administer with other ammonia lowering therapies, such as alternate pathway medications, hemodialysis, and protein restriction

Chronic hyperammonemia

  • Indicated as maintenance therapy for chronic hyperammonemia due to NAGS deficiency
  • 10-100 mg/kg/day PO/NG divided in 2-4 doses; round to the nearest 100 mg
  • During maintenance, concomitant use of other ammonia lowering therapies and protein restriction may be needed based on plasma ammonia levels

Hyperammonemia Due to PA or MMA

Indicated as adjunctive therapy to standard of care for acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA)

Initiate treatment of acute hyperammonemia in patients with a suspected or confirmed diagnosis of PA or MMA

3.3 g/m2/day PO divided into 2 equal doses (administered 12 hr apart) and round up to next multiple of 50 mg (ie, 1/4 of a tablet)

Continue treatment until ammonia level <50 micromol/L and for a maximum duration of 7 days

Use concomitantly with other ammonia lowering therapies, such as IV glucose, insulin, L-carnitine, protein restriction, and dialysis

Renal Impairment

No dosage adjustment warranted in patients with mild renal impairment (eGFR 60-89 mL/min/1.73 m2)

Hyperammonemia due to NAGS Deficiency

  • Moderate renal impairment (eGFR 30-59 mL/min/1.73 m2): 50 mg/kg/day to 125 mg/kg/day divided into 2 to 4 doses and rounded to nearest 50 mg (ie, one-quarter of a tablet)
  • Severe renal impairment (eGFR ≤29 mL/min/1.73 m2): 15 mg/kg/day to 60 mg/kg/day divided into 2 to 4 doses and rounded to nearest 50 mg (ie, one-quarter of a tablet)

Chronic Hyperammonemia due to NAGS Deficiency

  • Moderate renal impairment (eGFR 30-59 mL/min/1.73 m2): 5 mg/kg/day to 50 mg/kg/day divided into 2 to 4 doses and rounded to nearest 50 mg (ie, one-quarter of a tablet)
  • Severe renal impairment (eGFR ≤29 mL/min/1.73 m2): 2 mg/kg/day to 25 mg/kg/day divided into 2 to 4 doses and rounded to the nearest 50 mg (ie, one-quarter of a tablet)

Acute hyperammonemia due to PA or MMA

  • Moderate renal impairment (eGFR 30-59 mL/min/1.73 m2): 1.7 g/m2/day; divide daily dosage into 2 equal doses and round up to nearest 50 mg (ie, one-quarter of a CARBAGLU tablet); administer each dose 12 hours apart
  • Severe renal impairment (eGFR ≤29 mL/min/1.73 m2): 0.55 g/m2/day; divide daily dosage into 2 equal doses and round up to nearest 50 mg (ie, one-quarter of a tablet); administer each dose 12 hours apart

Dosing Considerations

Monitoring parameters

  • Closely monitor plasma ammonia levels
  • Titrate dosage to maintain the plasma ammonia level within normal range for age, taking into consideration the patient’s clinical condition (eg, nutritional requirements, protein intake, growth parameters

Dosage Forms & Strengths

dispersible tablet

  • 200mg

Hyperammonemia Due to NAGS Deficiency

Initiate treatment as soon as N-acetylglutamate synthase (NAGS) deficiency is suspected, which may be at birth

Acute hyperammonemia

  • Indicated as adjunctive therapy to standard of care for acute hyperammonemia due to NAGS deficiency
  • 100-250 mg/kg/day PO divided into 2-4 doses; round to the nearest 100 mg (ie, half of a tablet)
  • During acute episodes, administer with other ammonia lowering therapies, such as alternate pathway medications, hemodialysis, and protein restriction

Chronic hyperammonemia

  • Indicated as maintenance therapy for chronic hyperammonemia due to NAGS deficiency
  • 10-100 mg/kg/day PO/NG divided in 2-4 doses; round to the nearest 100 mg
  • During maintenance, concomitant use of other ammonia lowering therapies and protein restriction may be needed based on plasma ammonia levels

Hyperammonemia Due to PA or MMA

Indicated as adjunctive therapy to standard of care for acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA) in adults and children

Initiate treatment of acute hyperammonemia in patients with a suspected or confirmed diagnosis of PA or MMA

≤15 kg: 150 mg/kg/day PO

>15 kg: 3.3 g/m2/day PO

Divided into 2 equal doses (administered 12 hr apart) and round up to next multiple of 50 mg (ie, 1/4 of a tablet)

Continue treatment until ammonia level <50 micromol/L and for a maximum duration of 7 days

Use concomitantly with other ammonia lowering therapies, such as IV glucose, insulin, L-carnitine, protein restriction, and dialysis

Renal Impairment

No dosage adjustment warranted in patients with mild renal impairment (eGFR 60-89 mL/min/1.73 m2)

Hyperammonemia due to NAGS Deficiency

  • Moderate renal impairment (eGFR 30-59 mL/min/1.73 m2): 50 mg/kg/day to 125 mg/kg/day divided into 2 to 4 doses and rounded to nearest 50 mg (ie, one-quarter of a tablet)
  • Severe renal impairment (eGFR ≤29 mL/min/1.73 m2): 15 mg/kg/day to 60 mg/kg/day divided into 2 to 4 doses and rounded to nearest 50 mg (ie, one-quarter of a tablet)

Chronic Hyperammonemia due to NAGS Deficiency

  • Moderate renal impairment (eGFR 30-59 mL/min/1.73 m2): 5 mg/kg/day to 50 mg/kg/day divided into 2 to 4 doses and rounded to nearest 50 mg (ie, one-quarter of a tablet)
  • Severe renal impairment (eGFR ≤29 mL/min/1.73 m2): 2 mg/kg/day to 25 mg/kg/day divided into 2 to 4 doses and rounded to the nearest 50 mg (ie, one-quarter of a tablet)

Acute Hyperammonemia due to PA or MMA

  • Moderate renal impairment (eGFR 30-59 mL/min/1.73 m2):
    • ≤15 kg: 75 mg/kg/day f
    • >15 kg: 1.7 g/m2/day; divide daily dosage into 2 equal doses and round up to nearest 50 mg (ie, one-quarter of a CARBAGLU tablet); administer each dose 12 hours apart
  • Severe renal impairment (eGFR ≤29 mL/min/1.73 m2):
    • ≤15 kg: 25 mg/kg/day
    • > 15 kg: 0.55 g/m2/day; divide daily dosage into 2 equal doses and round up to nearest 50 mg (ie, one-quarter of a tablet); administer each dose 12 hours apart

Dosing Considerations

Monitoring parameters

  • Closely monitor plasma ammonia levels
  • Titrate dosage to maintain the plasma ammonia level within normal range for age, taking into consideration the patient’s clinical condition (eg, nutritional requirements, protein intake, growth parameters)
Next:

Adverse Effects

>10%

Acute and chronic hyperammonemia due to NAGS deficiency

  • Vomiting (26%)
  • Abdominal pain (17%)
  • Pyrexia (17%)
  • Tonsillitis (17%)
  • Anemia (13%)
  • Diarrhea (13%)
  • Ear infection (13%)
  • Infections (13%)
  • Nasopharyngitis (13%)
  • Hemoglobin decreased (13%)
  • Headache (13%)

Acute hyperammonemia due to PA and MMA

  • Neutropenia (14%)
  • Anemia (12%)

1-10%

Acute and chronic hyperammonemia due to NAGS deficiency

  • Dysgeusia (9%)
  • Asthenia (9%)
  • Hyperhidrosis (9%)
  • Influenza (9%)
  • Pneumonia (9%)
  • Weight decreased (9%)
  • Anorexia (9%)
  • Somnolence (9%)
  • Rash (9%)

Acute hyperammonemia due to PA and MMA

  • Vomiting (7%)
  • Electrolyte imbalance (7%)
  • Decreased appetite (5%)
  • Hypoglycemia (5%)
  • Lethargy/stupor (5%)
  • Encephalopathy (5%)
  • Pancreatitis/lipase increased (5%)
  • Cardiomyopathy (2%)
  • Alanine aminotransferase increased (2%)
  • Aspartate aminotransferase increased (2%)
  • Infusion site extravasation (2%)
  • White blood cell count increased (2%)
  • Behavior disorder (2%)
  • Sleep disorder (2%)
  • Apnea (2%)
  • Hyperventilation (2%)

Postmarketing Reports

Psychiatric disorders: Mania

Skin and subcutaneous tissue disorders: Pruritus, rash including rash erythematous, rash maculopapular, rash pustular

Previous
Next:

Warnings

Contraindications

None

Cautions

Plasma concentrations of carglumic acid increased in patients with renal impairment; reduce the dosage in patients with moderate or severe renal impairment; the pharmacokinetics of carglumic acid have not been evaluated in patients with end stage renal disease

Hyperammonemia

  • Monitor serum ammonia levels and adjust dose to maintain within normal range for age
  • Treat acute hyperammonemia episode as life-threatening emergency
  • Treatment of severe hyperammonemia may require dialysis, preferably hemodialysis and/or hemofiltration, to reduce plasma ammonia concentration
  • Untreated hyperammonemia can result in brain damage and death, and prompt use of all therapies necessary to reduce plasma ammonia level is essential
  • Protein restriction during an acute hyperammonemic episode is recommended for no longer than 12-36 hr while maximizing caloric supplementation to reverse catabolism; protein should be reintroduced as early as possible, following improvement of metabolic and clinical abnormalities in this setting; during long-term management, dietary protein restriction should be instituted to maintain blood ammonia level within an acceptable range for age
  • Ongoing monitoring of plasma ammonia level, neurological status, growth parameters, protein intake/nutritional status (both during acute hyperammonemic episodes and long-term), and relevant laboratory tests in patients receiving therapy should be part of evaluating clinical response to treatment
Previous
Next:

Pregnancy & Lactation

Pregnancy

Rare case reports of use in pregnant women are insufficient to inform a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes

Pregnancy pharmacovigilance program for carglumic acid exposures: 1-888-575-8344

Pregnant females with urea cycle disorders may experience an increase in catabolic stress which can trigger a hyperammonemic crisis both in intrapartum and in postpartum (3-14 days post-partum) periods

Maternal complications related to hyperammonemic crisis can include neurological impairment, coma and in some cases death

Animal data

  • Decreased survival and growth occurred in offspring born to rats that received carglumic acid at a dose ~38x maximum reported human maintenance dose

Lactation

Unknown whether drug is excreted in human milk

Present in rat milk, and an increase in mortality and impairment of body weight gain occurred in neonatal rats nursed by mothers receiving carglumic acid

Breastfeeding is not recommended during therapy; treatment is continuous and life-long for NAGS deficiency patients

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Previous
Next:

Pharmacology

Mechanism of Action

Structural analogue of N-acetylglutamate (NAG), which is produced from glutamate and acetyl-CoA in a reaction catalyzed by N-acetylglutamate synthase (NAGS), a mitochondrial liver enzyme

NAG acts as an essential allosteric activator of carbamoyl phosphate synthetase 1 (CPS 1), a mitochondrial liver enzyme which catalyzes the first reaction of the urea cycle

Carglumic acid acts as a CPS1 activator in patients with NAGS deficiency, thereby removing the block in the urea cycle and facilitating ammonia detoxification and urea production

Absorption

Peak plasma concentration: 8,613 ng/mL (8 mg/kg IV); 3,284 ng/mL (100 mg/kg PO)

Peak plasma time: 2 hr (8 mg/kg IV); 3 hr (100 mg/kg PO)

AUC: 24,501 ng·hr/mL (8 mg/kg IV); 31,426 ng·hr/mL (100 mg/kg PO)

Absolute bioavailability: ~10% (100 mg/kg PO)

Distribution

Vd: 15 L/kg (8 mg/kg IV)

Carglumic acid is not bound to plasma proteins

Metabolism

Proportion of carglumic acid may be metabolized by intestinal bacterial flora

Likely end product of metabolism is carbon dioxide, eliminated through the lungs

Elimination

Half-time: 31 hr (8 mg/kg IV); 25 hr (100 mg/kg PO)

Clearance: 0.34 L/hr/kg (8 mg/kg IV)

Excretion: Urine (9%, unchanged); feces (up to 60%)

Previous
Next:

Administration

Oral Preparation

Add ~2.5 mL of water into a small cup for each tablet or each 1/2 or 1/4 tablet needed for prescribed dose

Tablets do not dissolve completely in water and undissolved tablet particles may remain in mixing container

Add tablet(s) to water in cup

Carefully stir tablet and water mixture and administer immediately

Oral Administration

Do not swallow tablet whole or crush

Take immediately before meals or feedings

Suspension has a slightly acidic taste

For all preparations, use in foods or liquids, other than water, has not been studied clinically and is not recommended

Orally

  • Swallow mixture immediately after dispersing tablet
  • Pieces of tablet may remain in cup
  • Rinse cup with additional water and swallow mixture immediately; repeat until no tablet pieces are left in cup

Nasogastric

  • Draw up mixture into a catheter-tip syringe
  • Administer mixture immediately through nasogastric (NG)-tube or Gastrostomy (G)-tube
  • Pieces of tablet may remain in catheter-tip syringe, NG-tube, or G-tube
  • Flush immediately with 1-2 mL of additional water to clear NG-tube or G-tube
  • Flush NG-tube or G-tube again, as needed, until no pieces of tablet are left in syringe, NG-tube, or G-tube

Oral syringe

  • Draw up mixture in oral syringe and administer immediately
  • Pieces of tablet may remain in oral syringe
  • Refill oral syringe with a minimum volume of water (1-2 mL) and administer immediately
  • Flush oral syringe again, as needed, until no pieces of tablet are left in syringe

Storage

Unopened container: Refrigerate at 2-8ºC (36-46ºF)

Opened container

  • Store at room temperature between 15-30ºC (59-86ºF); do NOT refrigerate
  • Keep container tightly closed between openings to protect from moisture
  • Write date of opening on container; discard 1 month after first opening
  • Do not use after the expiration date stated on container
  • Keep out of reach of children
Previous
Next:

Images

BRAND FORM. UNIT PRICE PILL IMAGE
carglumic acid oral
-
200 mg tablet

Copyright © 2010 First DataBank, Inc.

Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Next:

Formulary

FormularyPatient Discounts

Adding plans allows you to compare formulary status to other drugs in the same class.

To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.

Adding plans allows you to:

  • View the formulary and any restrictions for each plan.
  • Manage and view all your plans together – even plans in different states.
  • Compare formulary status to other drugs in the same class.
  • Access your plan list on any device – mobile or desktop.

The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.

Tier Description
1 This drug is available at the lowest co-pay. Most commonly, these are generic drugs.
2 This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.
3 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.
4 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
5 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
6 This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
NC NOT COVERED – Drugs that are not covered by the plan.
Code Definition
PA Prior Authorization
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
QL Quantity Limits
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
ST Step Therapy
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
OR Other Restrictions
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Additional Offers
Email to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Email Forms to Patient

From:

To:

The recipient will receive more details and instructions to access this offer.

By clicking send, you acknowledge that you have permission to email the recipient with this information.

Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.